Look at the performance of Sanofi in China, the manufacturer of "anticoagulant first medicine".

Medicines Network February 7, 2016, Sanofi announced a break-up with Minsheng Pharmaceuticals, shocked most of the pharmaceutical communityAlthough Sanofi's joint venture has not been smooth, its own products have performed well at home as the first multinational pharmaceutical companies to enter ChinaHere's an analysis of Sanofi to see how his family is doing in the domestic marketSanofi, the, is a global leadingformedicinehealthcompanies in three areas: pharmaceuticals, human vaccines and animalhealthIn the pharmaceutical sector, Sanofi has innovative products in the field of prescription drugs such as blood and hematopoietic diseases, cardiovascular diseases, diabetes, tumors, and central nervous system diseasesIn 1982, Sanofi opened an office in China, joining the first multinational pharmaceutical companies to enter ChinaAccording to Informa Pharma Intelligence's 2016 Global 100 Mandatory Pharmaceutical Companies Ranking, Sanofi ranked fourth among pharmaceutical companies with $38.355 billion in sales (based on 2015 sales)Sanofi was ranked 9th in 2015 with 1.42 percent of the market in Chinese mainland, according to's CMH dataSanofi's market share was relatively stable in the Chinese market in 2013-2015 and is expected to increase in 2016 (Figure 1)heavy product analysis 　　FirstWordPharma's 2015 global brand drug sales of Top100 reached $265 billion (prescription drugs), of which Sanofi has five products (insulin injections (when it comes), hydrosulphate chlorpianogretablets (Polyvi), innoconoin sodium injections (Ksai) and two vaccine products) to enter the Top100 list, a total of $14.1 billion, accounting for 5.32 percent of the total Sanofi's main products have also made good progress in the Chinese domestic market Sanofi had three products shortlisted for the 2015 Top100 drug brand, namely the 2nd-ranked hydrochloride(Polyvi), the 63rd-ranked insulin glargine injection (when it came) and the 67th-largest Ebeshatan tablet (Amberview), which accounted for 3.79 percent of top 100, according to Zhongkang CMH as a diversified pharmaceutical health company, the number of products listed in China by the Foreign Enterprise Sanofi Group is second only to Bayer, mainly involving blood and hematopoietic system drugs, digestive system and metabolic drugs, cardiovascular system drugs, anti-tumor and immunomodulators, nervous system drugs, systemic anti-infective drugs and other broad areas (Figure 2)  Sanofi's main product markets 　　Blood and hematopoietic system drug Sanofi in the domestic blood and hematopoietic system drug use focus on the anti-thrombosis drug market Zhongkang CMH data show that in 2015 in the domestic market share of anti-thrombosis drugs accounted for 26.09 percent, firmly ranked 1st, of which hydrosulphate chloropio (Polyvi) contributed 24.11 percent of the share, inenohesin sodium injection (ksay) contributed 1.97 percent of the share Bolevi, known as "the first anticoagulant drug", by the French company Sanofi and the United States Squibb company in 1996 jointly developed success, and in March 1998 officially launched, has long been a drug under the drug, sales second only to Lipto, the world's second largest drug, in 2015 global sales of $2.14 billion in August 2001, Pollyvi was approved for sale in China, and before that the domestic chloropio gray's first imitation drug, Tyga, was approved for the market in 2000 and enjoyed an eight-year period of new drug protection With the expiration of the drug's administrative protection and new drug protection, the domestic ushered in the high tide of declaration imitation, as Boliwe and Tyga have covered most of the end of clopidogrel, follow-up imitations are difficult to shake the market pattern of chloropiogray, in 2015 Polly and Tyga accounted for 66.9% and 30.9% of the market share of the chloropidogl market, respectively ranked 46th in the top100 of global brand drug sales in 2015, with annual sales of $1,907 million, a gap of just over $200 million from Polyvi sales, but in the domestic anti-thrombosis drug market, the gap between the two shares is more than 20 percentage points From this gap, the market capacity of Thee has great room for improvement in China digestive system and metabolic drugs
Sanofi in the domestic digestive system and metabolic drugs in the field mainly focused on diabetes drugs and liver and bile drugs in the two sub-sub-markets According to Zhongkang CMH data, Sanofi accounted for 7.57 percent of the domestic diabetes drug market in 2015, ranking 3rd, with insulin injection (when it comes) contributing 5.02 percent, Gremmel tablets (Yamoli) contributing 2.52 percent; came in the world's top 100 in top sales of branded drugs in 2015, with annual sales of $7,088 million, making it the world's number one diabetes drug Launched in China in 2004, Zhongkang CMH data show that it accounted for 11.93 percent of insulin injections in 2015, down from No At the time of the domestic market position and the global market position compared to a certain gap, although in the face of Novo Nordisk, Lilly and other parties of the drug competition, and due to the expiration of patents are about to face the impact of generic drugs, but its market expansion in China is still worth looking forward to amoli as an oral sugar-reducing drug, and China's CMH data show that it accounted for 4.46 percent of the domestic oral sugar-reducing drug market in 2015, ranking 6th Oral sugar-lowering drug classification more, Yamoli belongs to the sulfonylurea category under the Gremmean, although the Grammys manufacturers are numerous, fierce market competition, Yamoli market performance is no less, market share increased year by year easy to recover is mainly used to help improve toxic liver damage (e.g drugs, poisons, chemicals and alcohol-induced liver damage) as well as loss of appetite in patients with fatty liver and hepatitis, right upper abdominal compression, etc According to Zhongkang CMH data, Yi Shanfu's market share in domestic liver therapeutic drugs in 2015 was 2.74 percent, ranking 9th There are two methods of administration, with oral capsules contributing 1.91% and injections contributing 0.82% of the market share cardiovascular system drug Sanofi focuses on the market for antihypertensive drugs (drugs acting on renin-angiotensin systems) in the field of cardiovascular system drugs in the country In 2015, Sanofi's market share in drugs acting on renin-angiotensin system (RAS) was 12.84 percent, second only to Novartis, with Ebeshatan tablets (Ambovi) contributing 8.55 percent, Ebeshatan hydrochloricine tablets (Ambono) contributing 3.83 percent and Remipri (Reta) contributing 0.47 percent, according to Zhongkang CMH anti-tumor and immunomodulators
Sanofi focuses on the anti-tumor drug market in the field of anti-tumor and immunomodulators in China In 2015, Sanofi ranked 9th in the market share of anti-tumor drugs with 3.29 percent, with osalyplatinum (Lesadin) contributing 1.67 percent, Dositamati injections (Tesotti) contributing 1.53 percent and antalytic ilico injections contributing 0.09 percent, according to Zhongkang CMH